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Summary
Background: Autoimmune hepatitis requires long‐term therapy, and systemic cor‐
ticosteroids are the backbone of therapeutic management. Prolonged use of corti‐
costeroids may lead to adverse events but data from long‐term studies are mainly 
derived from studies in rheumatic diseases.
Aim: To assess cataract, diabetes and fractures in relation to corticosteroid doses in 
the long‐term maintenance treatment of patients with autoimmune hepatitis.
Methods: We retrospectively collected data on 476 patients (77% women) with an 
established diagnosis of autoimmune hepatitis. Binary logistic regression with a gen‐
eralised estimating equation was used to analyse the association between current 
corticosteroid use and the incidence of cataract, diabetes and fractures with onset 
after autoimmune hepatitis diagnosis. We corrected for sex, age, cirrhosis at diagno‐
sis and predniso(lo)ne use in the prior 3 years to account for possible ongoing effects.
Results: A total of 6634 years, with a median of 13 (range 1‐40) per patient were 
recorded. The median age at diagnosis was 44 years (range 2‐88). Adverse events 
were documented in 120 (25%) patients. Low‐dose predniso(lo)ne (0.1‐5.0 mg/d) in‐
creased the odds of fractures whereas higher doses (>5.0 mg/d) increased the odds 
of cataracts and diabetes. Budesonide increased the odds of cataract and fractures; 
this effect was independent of predniso(lo)ne use in the prior 1, 2 or 3 years.
Conclusions: Even low doses of corticosteroids frequently lead to substantial ad‐
verse events refuting the assumption that adverse events are prevented by adminis‐
tering low doses.
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1  | INTRODUC TION
Autoimmune hepatitis is a severe immune‐mediated inflammation 
of unknown aetiology that primarily targets hepatocytes. Treatment 
is aimed to prevent disease relapse, relieve symptoms and achieve 
full biochemical and histological normalisation in order to prevent 
progression to fibrosis, cirrhosis and end‐stage liver failure requiring 
liver transplantation. Since the introduction of prednisone, survival 
has improved dramatically.1 Unfortunately, most patients require life‐
long immunosuppressive therapy, as relapse after cessation of ther‐
apy has been shown in up to 90% of patients.2 In early clinical trials, it 
was found that the addition of azathioprine decreased steroid‐related 
side effects and that this combination was as effective as prednisone 
alone. Currently, treatment regimens for autoimmune hepatitis are 
based on these trials and 44%‐75% of patients require a glucocortico‐
steroid‐based maintenance therapy, with or without azathioprine.3,4 
Up to 30% of these patients may suffer from corticosteroid‐related 
side effects, including diabetes, osteoporotic fractures, cataract, hy‐
pertension, cushingoid appearance and weight gain.5 Corticosteroid‐
specific side effects are thought to arise in autoimmune hepatitis 
patients on doses exceeding 7.5‐10 mg/d predniso(lo)ne when admin‐
istered over several months and it is advocated to reduce the dose 
below this threshold to prevent adverse events.6 However, studies on 
dose‐related side effects of corticosteroids supporting this assump‐
tion have predominantly been performed in rheumatic diseases, and 
data on the prevalence of side effects in patients with autoimmune 
hepatitis on long‐term corticosteroids are scarce.7
In this study, we focused on three frequently occurring and 
documented adverse events. We aimed to assess the incidence of 
cataract, diabetes and osteoporotic fractures in relation to cortico‐
steroid doses in the long‐term maintenance treatment of patients 
with autoimmune hepatitis.8
2  | MATERIAL S AND METHODS
The registry of the Dutch Autoimmune Hepatitis Study Group con‐
tains data from autoimmune hepatitis patients, the collection of data 
started in 2008 and is ongoing. The cohort of this study was described 
in detail in a previous study.9 All patients fulfilled the revised score of 
the International Autoimmune Hepatitis Study Group with a probable 
or definite diagnosis of autoimmune hepatitis.9,10 The study protocol 
(number 2008.84) was approved by the institutional review boards of 
all participating tertiary referral (n = 6) and general hospitals (n = 10) 
in the Netherlands. Medical records of 506 patients were retrospec‐
tively reviewed; 20 did not have available treatment regimen data and 
were excluded; 10 patients with cirrhosis at diagnosis who were pre‐
scribed budesonide during the disease course were excluded.
The clinical characteristics including adverse events and 
treatment regimen of 476 patients were collected for analysis. 
Maintenance therapy was recorded as the mean dose of medication 
per milligram per day over each follow‐up year. Cataracts, diabetes 
and fractures with an onset after the date of autoimmune hepatitis 
diagnosis were considered as new‐onset and registered for this study. 
Cataracts were defined as patients being subjected to cataract sur‐
gery or as determined by the ophthalmologist or the attending phy‐
sician. Diabetes was defined as determined by the treating physician 
and by the requirement of initiation of treatment (diet change, oral 
anti‐diabetics or insulin). Fractures that occurred after the diagnosis 
of autoimmune hepatitis were assessed using the emergency room 
and surgery reports and imaging reports. Normal bone density, 
osteopenia and osteoporosis were defined as T‐scores above −1.0; 
−1 to −2.5 and −2.5 or lower respectively. Autoimmune hepatitis 
variants with concurrent primary biliary cholangitis (AIH‐PBC) and 
autoimmune hepatitis with features of primary sclerosing cholangitis 
(AIH‐PSC) were defined according to the current guidelines.11,12
2.1 | Statistical analysis
Normally distributed variables were described as mean with stand‐
ard deviation (SD), whereas nonnormally distributed variables were 
described as median with range. Categorical data were described 
as numbers and percentages of the total. Binary logistic regression 
with a generalised estimating equation was used to analyse the as‐
sociation between the occurrence of adverse events and predictors. 
Adverse events which occurred before the diagnosis of autoimmune 
hepatitis were discarded. In the case of multiple fractures in one 
patient, only the date of the first fracture was used in the model. 
Factors that were possibly predictive of adverse events and that 
were available in the database, were included simultaneous in the 
multivariate model to provide estimates adjusted for other factors/
predictors. The doses of immunosuppressive therapy and the oc‐
currence of adverse events were analysed per patient per follow‐up 
year. For every year, a patient was at risk of developing an adverse 
event, the age in that year was used. By these means, ageing was 
taken into account. In addition, the effect of the predniso(lo)ne dose 
in the prior years was assessed. Patient‐years without the use of 
predniso(lo)ne or budesonide were used as reference categories. 
The outcome is described as an estimation of the odds ratio with 
its 95% CI. The level of significance (α) was set at 0.05. Statistical 
analyses were performed with IBM SPSS 22.0.
3  | RESULTS
A total of 476 patients with a median follow‐up time of 13 years 
(range 1‐40) who were treated in 16 hospitals in the Netherlands 
were included (Table 1). Paediatric onset (<18 years) of the disease 
was present in 68 (14%) of the patients at a median age of 14 years. 
The majority (96%; n = 65) of these patients with a paediatric onset 
had predominantly been followed during adulthood years. Details 
of immunosuppressive therapy are shown in Table 2. Complete bio‐
chemical remission was achieved in 424 (90%) patients, whereas 47 
(10%) patients did not. The predominantly prescribed medications 
were predniso(lo)ne and azathioprine. In total, 428 (90%) patients 
were prescribed predniso(lo)ne. Of the years that predniso(lo)ne was 
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used in these patients, the mean daily dose was ≤ 5.0 mg (n = 96; 
20%), 5.1‐10 mg (n = 272; 56%) or > 10 mg (n = 67; 14%). Budesonide 
was prescribed to 84 (17%) patients in mean daily doses of 0.1‐3 mg 
(n = 17; 4%), >3.0 mg (n = 67; 14%). A total of 367 (77%) patients 
had received combination therapy with both predniso(lo)ne and aza‐
thioprine, during a median time of 5 years (range 1‐29). Cirrhosis on 
histology was present at diagnosis in 64 (17%) of the patients and 
developed in another 22 (5%) patients during therapy.
3.1 | Adverse events
In 120 (25%) patients cataract, diabetes or one or more fractures 
occurred after the diagnosis of autoimmune hepatitis. The effect of 
one additional daily milligram predniso(lo)ne or budesonide on the 
odds of developing any of the studied side effects, corrected for 
age and sex is shown in Table 3. For example, adding 1 milligram of 
predniso(lo)ne increased the odds of a first combined primary side 
effect by 8%; two additional milligrams of predniso(lo)ne would in‐
crease the odds by 17%. There was no relation between the response 
to treatment and the occurrence of any of the adverse events. The 
effects of predniso(lo)ne and budesonide doses on the odds of cata‐
ract and fracture, with and without a correction for predniso(lo)ne 
use in the year prior to the adverse event are shown in Figure 1.
Cataracts in either one or both eyes developed in 45 (9%) pa‐
tients at a median age of 66 years (range 36‐86). In generalised esti‐
mating equations, predniso(lo)ne doses exceeding 5 mg/d increased 
(P = .018) the odds of cataract, corrected for budesonide use, sex and 
the age at that year (Figure 1, panel A). Cirrhosis did not increase the 
odds of cataract (OR 0.7; CI 0.6‐2.0 P = .6). The effect of predniso(lo)
ne on the odds of cataract persisted for 1 year (P < .001), whereas 
predniso(lo)ne doses 2 years (P = .8) or 3 years (P = .2) before did not 
increase the odds of cataract (Figure 1, panel B). Budesonide use 
 Autoimmune hepatitis AIH‐PBC AIH‐PSC
Patients, n (%) 406 (87) 30 (6) 40 (9)
Female, n (%) 315 (78) 27 (90) 24 (60)
Age in years, median 
(range)
46 (2‐88) 46 (16‐70) 31 (12‐77)
MELD‐score, median 
(range)
10 (0‐32) 7 (1‐22) 8 (1‐17)
IgG g/L, median (range) 26 (7‐91) 22 (8‐59) 22 (13‐51)
ALT U/L, median 
(range)
513 (11‐4693) 268 (18‐2649) 273 (46‐2500)
Cirrhosis, n (%) 57 (18) 4 (14) 3 (9)
ANA and or SMA posi‐
tive, n (%)
333 (88) 20 (72) 32 (91)
ANA positive, n (%) 268 (74) 13 (43) 23 (70)
SMA positive, n (%) 217 (63) 15 (60) 20 (59)
Abbreviations: AIH‐PBC, autoimmune hepatitis with concomitant primary biliary cholangitis; 
AIH‐PSC, autoimmune hepatitis with concomitant primary sclerosing cholangitis; ALT, alanine 
aminotransferase; ANA, anti‐nuclear antibody; IgG, immunoglobulin G; MELD, model for end‐stage 
liver disease; SMA, smooth muscle antibody.
TA B L E  1   Characteristics at diagnosis
TA B L E  2   Treatment details of patients with autoimmune hepatitis
 
Years of medication use
n (%)a
Patients
n (%)
Years of use, median 
(range)
Dose mg/d median 
(range)
Predniso(lo)ne 3767 (57) 429 (90) 7 (1‐39) 8 (1.67‐33.75)
Budesonide 449 (7) 85 (18) 4 (1‐16) 6 (1‐12)
Azathioprine 4541 (68) 392 (82) 12 (1‐34) 73 (4‐500)
Mycophenolate mofetil 195 (3) 33 (7) 6 (1‐15) 1000 (50‐4000)
Ciclosporin 66 (1) 11 (2) 6 (1‐14) 138 (13‐400)
Tacrolimus 28 (0) 6 (1) 5 (1‐8) 5 (0.7‐12.0)
Mercaptopurine 60 (1) 15 (3) 2 (1‐21) 50 (1‐100)
Tioguanine 35 (1) 9 (2) 2 (1‐10) 18 (3‐50)
Allopurinol 39 (1) 14 (3) 3 (1‐6) 100 (50‐100)
Ursodeoxycholic acid 1661 (25) 164 (34) 11 (1‐28) 825 (50‐1800)
aThe total patient‐years was 6634. 
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increased the odds of cataract (P = .023); this effect was indepen‐
dent (P = .021) of predniso(lo)ne use in the prior 1, 2 or 3 years.
A total of 102 fractures occurred in 69 (15%) patients, at a me‐
dian age at the first fracture of 64 years (range 14‐88). Cirrhosis 
did not increase the odds of a fracture (OR 0.6; CI 0.3‐1.3 P = .1). 
Predniso(lo)ne (0.1‐5.0 mg/d) and budesonide were predictive of 
one or more fractures (Figure 1, panel C), corrected for sex and the 
age in that year. The predniso(lo)ne and budesonide‐associated 
increase in odds ratio persisted after correction for predniso(lo)
ne use in the prior year before the fracture (Figure 1, panel D). 
Predniso(lo)ne use in the prior one (P = .6), two (P = .9) or three 
(P = .8) years did not influence the odds of a fracture. The different 
types of fractures that were observed include vertebral compres‐
sion (n = 36; 35%), femur or hip (n = 12; 11%), pelvis (n = 1; 1%), 
tibia or fibula (n = 9; 9%), humerus or radius or ulna (n = 21; 20%), 
(meta)carpal (meta)tarsal or phalanx bones (n = 15; 15%), rib (n = 5; 
5%), nasal bone (n = 1; 1%), patella (n = 1; 1%) and transverse pro‐
cess fractures (n = 1; 1%). Osteoporotic vertebral fractures can 
occur asymptomatic and slowly over time, subsequently the date 
of diagnosis on X‐ray can be different from the onset. Hence, a 
sub analysis including fractures with a preceding trauma and ex‐
cluding vertebral fractures was performed. This analysis further 
characterised the effect of predniso(lo)ne (0.1‐5.0 mg/d), but not 
of budesonide (Figure S1) on nonvertebral fractures. Predniso(lo)
TA B L E  3   Increase in odds ratio of adverse events for each additional milligram of corticosteroid dose
Possible adverse events
Predniso(lo)ne
P value
Budesonide
P valueOdds ratio (95% CI) Odds ratio (95% CI)
Combined primary adverse 
events
1.08 1.06‐1.11 <.001 1.09 1.00‐1.20 .06
Primary adverse event
Cataract 1.06 1.03‐1.10 <.001 1.17 1.02‐1.33 .02
Diabetes 1.09 1.05‐1.12 <.001 0.96 0.70‐1.30 .78
Bone fracture 1.05 1.01‐1.10 .01 1.14 1.03‐1.27 .02
Note: Generalised estimated equations, corrected for sex and age at that year.
F I G U R E  1   The effect of predniso(lo)ne and budesonide on the odds of cataract (panels A and B) or fracture (panels C and D) or diabetes 
(panels E and F). The asterisk indicates the reference category of patient‐years that no predniso(lo)ne or budesonide was used. The odds 
ratios of adverse events are uncorrected (panel A, C and E) or corrected for predniso(lo)ne use in the prior year (panel B, D and F)
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ne use in the prior 1 (P = .5), 2 (P = .9) or 3 (P = .2) years did not in‐
fluence the odds of a nonvertebral fracture. Data on bone density 
in patients with one or more fractures were available in 49 of 69 
patients and showed a normal bone density (10%; n = 5), osteo‐
penia (53%; n = 26) or osteoporosis (37%; n = 18). Bone density 
data were available in 261 of 407 patients without a fracture and 
showed a normal bone density (37%; n = 96), osteopenia (49%; 
n = 128) or osteoporosis (14%; n = 37). In 13 hospitals (n = 369 
patients), data on treatment to prevent bone loss were available. 
Medication to prevent or treat bone loss was prescribed to 265 
(72%) patients and consisted of calcium carbonate (n = 247; 67%), 
vitamin D (n = 210; 57%), bisphosphonate (n = 165; 45%) and de‐
nosumab (n = 3; 1%). In these 13 hospitals, all patients (n = 42) 
who had been diagnosed with osteoporosis and 97 of 110 patients 
with osteopenia have received bone protective therapy. Patients 
who were treated for bone loss, where not at different odds of a 
fracture (OR 1.3; CI 0.7 2.6 P = .3).
New‐onset diabetes developed in 46 (10%) patients at a me‐
dian age of 60 years (range 29‐86). Both moderate (5.1‐10.0 mg/d) 
and higher (>10 mg/d) doses of predniso(lo)ne doses increased the 
odds of diabetes when corrected for budesonide, cirrhosis at di‐
agnosis, age and sex (Figure 1, panel E). Eighteen of the cases with 
new‐onset diabetes (39%) occurred in the first year after autoim‐
mune hepatitis diagnosis and start of treatment. In those patients 
with diabetes onset after more than 1 year (n = 28), previous high‐
dose prednisolone exposure (>10mg/day) in the previous year was 
a significant predictor (P = .05, Figure 1F). The effect of pred‐
niso(lo)ne on the odds of diabetes persisted for 1 year (P = .05), 
whereas predniso(lo)ne doses 2 years (P = .3) or 3 years (P = .1) 
before did not increase the odds of diabetes (Figure 1 panel F). 
Only one case of new‐onset diabetes occurred in a patient using 
both predniso(lo)ne and budesonide in high daily doses of >10 and 
>3.0 mg respectively. The effect of budesonide on new‐onset dia‐
betes could not be established.
We have performed additional analyses after excluding paedi‐
atric onset patients and found that this did not change the results 
for cataract and diabetes. The effect of current year predniso(lo)ne 
in high‐dose (>10 mg) on the odds of a fracture was slightly more 
pronounced in the analysis with adult onset only (OR 2.9; 1.0‐7.8).
3.2 | Patients with autoimmune hepatitis 
variant syndromes
The odds of cataract, diabetes and fractures was similar when pa‐
tients with an autoimmune hepatitis variant with primary biliary 
cholangitis or primary sclerosing cholangitis were excluded from 
analysis (data not shown). Patients with autoimmune hepatitis vari‐
ants were prescribed mycophenolate mofetil more often compared 
with patients with autoimmune hepatitis (data not shown). No sig‐
nificant differences were observed in predniso(lo)ne, budesonide, 
azathioprine, mercaptopurine, tioguanine (thioguanine), tacrolimus 
and cyclosporine prescriptions, between autoimmune hepatitis and 
autoimmune hepatitis variant patients.
4  | DISCUSSION
The results of this study re‐establish the fracture risk in patients 
taking corticosteroids. Here we show that in patients with autoim‐
mune hepatitis, this fracture risk is already increased at low‐doses 
corticosteroid use. In addition, we show that the odds of all studied 
adverse events increase with corticosteroid use.
Oral predniso(lo)ne use increased the odds of all studied side 
effects in our cohort; cataract, diabetes and fractures. The mech‐
anism of action of glucocorticoids via the cytosolic or membrane‐
bound glucocorticoid receptor is dose‐dependent.13 Likewise, the 
occurrence of adverse events increases with increasing doses in 
our and other studies.14‐16 In our cohort, the odds of new‐onset 
fractures increased even when low average doses of ≤5 mg pred‐
niso(lo)ne was prescribed, whereas the odds of diabetes and cat‐
aract increased at a threshold of >5 mg predniso(lo)ne daily. We 
observed that the effect of predniso(lo)ne dose on the occurrence 
of cataract and diabetes persisted for 1 year and did not observe 
this effect for predniso(lo)ne in the prior 2 or 3 years, implicating 
that discontinuing glucocorticoids decreased the odds of adverse 
events. Vertebral compression fractures are the most common 
type of low‐trauma osteoporotic fractures and were the most fre‐
quent observed fractures in our cohort. This is in line with a large 
study from the United Kingdom that found an increased risk of 
vertebral compression fractures even with low‐dose predniso(lo)
ne (2.5 mg/d).17 Accurate ‘dating’ of these often nontraumatic frac‐
tures can be challenging due to an asymptomatic course. However, 
predniso(lo)ne was significantly associated with nonvertebral frac‐
tures, suggesting that this is indeed a risk factor for osteoporosis 
related fractures.
In our cohort, we observed that budesonide use increased the 
odds of fractures and cataract. This effect persisted after correc‐
tion for predniso(lo)ne use in the years prior to these events, sug‐
gesting that the ‘topically’ acting budesonide does not completely 
prevent an increase in the odds of fractures or cataract and may be 
an independent risk factor for these adverse events. However, it 
should be noted that despite efforts to control for prior exposure of 
predniso(lo)ne, this may have influenced the outcome of the odds of 
budesonide. As only one patient developed de novo diabetes while 
treated with budesonide, we could not establish a possible effect 
on the odds of this event. Overall, budesonide seems to have a fa‐
vourable adverse event profile which is consistent with Danielsson 
et al18 who found a low frequency of adverse events in patients with 
autoimmune hepatitis treated with budesonide after prior occur‐
rence of prominent side effects on prednisone. In addition, Manns 
et al19 found significantly less short‐term corticosteroid‐specific side 
effects in autoimmune hepatitis patients treated with budesonide 
compared to predniso(lo)ne. This is supported by evidence in the 
long‐term treatment of patients with inflammatory bowel disease 
with budesonide.20
A separate analysis provided a detailed assessment of the effect 
of each additional milligram of daily corticosteroid doses, with sex 
and age being equal; one additional milligram of daily predniso(lo)
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ne increased the odds of a first side effect in that year by 8%. 
Correspondingly, a patient with two additional milligrams of pred‐
niso(lo)ne per day would face a 17% increase of the odds of any of 
the studied adverse effects compared with patients without these 
additional two milligrams.
Side effects of corticosteroids are well assessed in diseases such as 
rheumatoid arthritis,16 systemic lupus erythematosus,21 inflammatory 
bowel disease,22 chronic idiopathic urticaria23 or asthma24 where oral 
predniso(lo)ne is frequently used. Yet, the relationship between corti‐
costeroid dose and adverse events is not well quantified. The standard 
immunosuppression that was applied in the classic early clinical trials in 
autoimmune hepatitis led to a high prevalence of corticosteroid‐related 
side effects.1 With the introduction of azathioprine in the treatment of 
autoimmune hepatitis, both doses and corticosteroid‐related adverse 
events decreased.25‐27 However, recently the International Autoimmune 
Hepatitis Study Group emphasised that concerns regarding corticoste‐
roid‐related adverse events are ongoing.28 The current study shows 
that even low‐dose strategies frequently lead to substantial side effects 
are at odds with the assumption that adverse events are prevented by 
low‐dose strategies. Yet, the finding that this effect mitigates after dis‐
continuing predniso(lo)ne is reassuring. A recent survey amongst expert 
hepatologists showed that azathioprine is a widely used corticosteroid‐
sparing agent, yet unfortunately often not optimised.29 Thiopurine ther‐
apy in autoimmune hepatitis patients with intolerance or insufficient 
response to azathioprine can be optimised by the addition of allopuri‐
nol,30 switching to tioguanine31 or mercaptopurine.32 Alternatively, my‐
cophenolate mofetil has been successfully applied in the treatment of 
autoimmune hepatitis.33 By these means, the steroid sparing effect can 
be improved and the risk of being started on other medications can be 
prevented. The strengths of this study are defined by the long follow‐up 
period of a large group of clinically characterised patients, the detailed 
analysis of daily doses of maintenance medication and the representa‐
tion of patients treated in both transplant, nontransplant and general 
referral hospitals. Yet, the results of our study may be affected by re‐
ferral bias, lifestyle or socio‐economic factors and under‐reporting as 
we could not assess adverse events with a nationwide method. On the 
contrary, with cross‐checking multiple data sources of each hospital, we 
have put effort into the complete capture of adverse events.
The focus of this study was limited to three adverse events. 
We choose to assess these adverse events because they occur fre‐
quently, have a major economic and quality of life impact and are 
usually well documented. Metabolic, neuropsychiatric, cardiovascu‐
lar and infectious complications of corticosteroids were not within 
the scope of this study. In addition, alternative analysis such as a 
propensity score or case‐control study could have strengthened our 
results, yet confounders for matching and data on incidence ratios 
of the general Dutch population in the studied time frame were not 
available. Finally, the types of cataracts were not distinguished in 
our cohort and we lumped the total number of cataracts that oc‐
curred and could not assess the proportion of corticosteroid‐related 
posterior subcapsular cataracts. Yet, the clear relation between 
new‐onset cataracts and corticosteroid use in our cohort suggests 
that posterior subcapsular cataracts were captured. The results of 
this study show that patients with autoimmune hepatitis on any dose 
of corticosteroids should be informed about the risk of cataract and, 
if indicated (ie due to an impaired vision), referred to an ophthalmol‐
ogist for eye examination.
5  | CONCLUSION
In conclusion, treatment with predniso(lo)ne increased the odds of 
cataract, diabetes and bone fractures in patients with autoimmune 
hepatitis. This increased odds of adverse events was dose‐depend‐
ent and appears to be reversible. An effect of budesonide on ad‐
verse events could not confidently be observed, but it appears not 
to prevent the development of fractures or cataracts.
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